Updates are available Correction dated 2024-12-23
Click to view Correction: https://doi.org/10.1007/s00401-024-02841-8
-
Authors
Moonen, Sebastiaan
Koper, Marta J.
Van Schoor, Evelien
Schaeverbeke, Jolien M.
Vandenberghe, Rik
von Arnim, Christine A. F.
Tousseyn, Thomas
De Strooper, Bart
Thal, Dietmar Rudolf https://orcid.org/0000-0002-1036-1075
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G065721N, G0F8516N, 1S46219N, 12Y1620N)
Onderzoeksraad, KU Leuven (DB/20/007/BM)
Internationale Stichting Alzheimer Onderzoek (#SAO-FRA 2021/00022)
- License Information
-
More Information
Article History
Received: 5 August 2022
Revised: 30 November 2022
Accepted: 1 December 2022
First Online: 9 December 2022
Change Date: 18 December 2024
Change Type: Update
Change Details: The original article has been corrected. Supplementary tables 1 and 3 were replaced.
Change Date: 23 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00401-024-02841-8
Declarations
:
: DRT is a member of the Acta Neuropathologica Editorial Board. He was not involved in the assessment or decision-making process for this manuscript. DRT received speaker honorary or travel reimbursement from UCB (Brussels, Belgium) and Biogen (USA), and collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug (Halle (Saale), Germany), GE Healthcare (Amersham, UK), and Janssen Pharmaceutical Companies (Beerse, Belgium). RV’s institution has a clinical trial agreement (RV as PI) with Alector, Biogen, J&J, NovoNordisk, Prevail, Roche and UCB. RV’s institution has a consultancy agreement for participation in Data Safety Monitoring Board (RV as provider) with AC Immune and Novartis. RV’s institution has a material transfer agreement (RV as PI) with ADx Neurosciences. CAFvA received honoraria from serving on the scientific advisory board of Biogen, Roche, Novo Nordisk, and Dr. Willmar Schwabe GmbH &Co. KG and has received funding for travel and speaker honoraria from Biogen, Roche diagnostics AG, Medical Tribune Verlagsgesellschaft mbH, and Dr. Willmar Schwabe GmbH &Co. KG and has received research support from Roche diagnostics AG. Bart De Strooper is occasionally consulting for different companies. He is founding scientist of Augustin TX and of Muna TX. He is also shareholder of Muna TX. Funders were not involved in the design of this study, in the collection, analysis or interpretation of data, in the decision to publish the results, or in the preparation of the manuscript.
: Human post-mortem brain tissue was collected in accordance with the applicable laws in Belgium (UZ Leuven) and Germany (Ulm). The recruitment protocols for the collection of human brains were approved by the ethical committees of the UZ Leuven (Belgium; S-59292, S-52791) and the University of Ulm (Germany; 54/08). This study was approved by the UZ Leuven ethical committee (Leuven, Belgium; S-64378).
